Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on Iclusig® (ponatinib) and AP26113, its investigational inhibitor of anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR) and c-ros oncogene (ROS1), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 31 to June 4, 2013.
Help employers find you! Check out all the jobs and post your resume.
